Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.26 USD | -0.66% | -6.29% | -19.59% |
May. 23 | Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment | MT |
May. 22 | Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.59% | 84.21B | |
+38.73% | 728B | |
+33.05% | 603B | |
-5.83% | 360B | |
+18.81% | 332B | |
+1.02% | 279B | |
+16.00% | 244B | |
+8.09% | 207B | |
-5.77% | 205B | |
+6.36% | 164B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint